Crohn’s disease Archives - Well Referenced

Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn’s Disease: A Randomized Controlled Clinical Trial

This 2018 randomized controlled trial assessed the safety and efficacy of umbilical cord-derived mesenchymal stem cells (UC-MSCs) in patients with moderate to severe Crohn’s disease (CD) unresponsive to long-term steroid therapy. Eighty-two patients were enrolled, with 41 receiving four weekly intravenous infusions of 1×10⁶ UC-MSCs/kg. After 12 months, the UC-MSC

June 26, 2025 No Comments

Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study

This nationwide longitudinal cohort study from Taiwan assessed whether inflammatory bowel disease (IBD) increases dementia risk. Using data from 1,742 IBD patients aged ≥45 and 17,420 matched controls, the study tracked dementia incidence over a 16-year period. Results showed IBD patients had a significantly higher risk of developing dementia (HR

June 26, 2025 No Comments

Inflammatory bowel disease increases the risk of Parkinson’s disease: a Danish nationwide cohort study 1977–2014

This 2019 Danish nationwide cohort study examined the long-term risk of Parkinson’s disease (PD) among individuals with inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. Using national registry data from 1977 to 2014, the study followed 76,477 IBD patients and over 7.5 million controls. Results showed a significantly

June 26, 2025 No Comments

Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis

This systematic review and meta-analysis evaluated the safety profile of oral naltrexone by analyzing serious adverse events (SAEs) reported in placebo-controlled randomized controlled trials (RCTs). A total of 89 RCTs involving 11,194 participants across various conditions—including alcohol use disorders, psychiatric disorders, impulse control disorders, obesity, Crohn’s disease, fibromyalgia, and cancer—were

June 26, 2025 No Comments

Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization

This 2018 review explores the pharmacological properties and therapeutic applications of low-dose naltrexone (LDN), defined as daily doses between 1 and 5 mg. LDN modulates the immune system by transiently blocking opioid receptors, leading to upregulation of endogenous opioids and reduction of pro-inflammatory cytokines via Toll-like receptor 4 (TLR4) antagonism.

June 26, 2025 No Comments

Utility of faecal calprotectin analysis in adult inflammatory bowel disease

This study explores the use of faecal calprotectin (FC) measurement as a non-invasive biomarker for diagnosing and managing inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). Elevated FC levels correlate with active disease and can help distinguish IBD from other gastrointestinal conditions like irritable bowel syndrome

June 26, 2025 No Comments

Calprotectin in inflammatory bowel disease

This review article explores the role of calprotectin as a key biomarker in inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. Elevated levels of calprotectin are closely associated with disease activity, making it an effective non-invasive marker for diagnosing IBD, assessing disease severity, monitoring treatment response, and predicting

June 26, 2025 No Comments

Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing

This 2017 observational study published in Gastroenterology (PMID: 28601482) examined the role of intestinal permeability in patients with Inflammatory Bowel Disease (IBD) who had achieved mucosal healing but continued to experience bowel symptoms. Among 88 IBD patients (31 with ulcerative colitis and 57 with Crohn’s disease), 16.3% reported ongoing symptoms

June 26, 2025 No Comments

Neuroprotective actions of methylene blue and its derivatives

This article examines the clinical pharmacology of curcumin, a compound found in turmeric, for treating inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. It discusses curcumin’s potent anti-inflammatory, antioxidant, and immunomodulatory effects that help reduce inflammation and promote healing in IBD patients. Clinical studies indicate a 40-50% improvement

June 26, 2025 No Comments

Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease

The article titled “Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease,” published in the American Journal of Gastroenterology (1998), examined the relationship between inflammatory markers and serum levels of adrenal hormones (DHEAS and cortisol) in patients with chronic

June 26, 2025 No Comments

Tag: Crohn’s disease